AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24467625 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients
Number of subjects: 29
Study 24467625 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine patients (males)
Number of subjects: 29
Study 24467625 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched participants (control)
Number of subjects: 29
Study 22776106 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG treatment (Xepol® 50 mg/ml)
Number of subjects: 41
Study 22776106 — intervention group
Group type: COMPARATOR
Intervention: Control (OND subjects)
Number of subjects: 41
Study 20553388 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal D-dimer, males younger than 65
Number of subjects: 1265
Study 20553388 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal D-dimer, patients aged 65 or older
Number of subjects: 1265
Study 20553388 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal D-dimer, overall recurrence rates
Number of subjects: 1265
Study 17405803 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance exercise group (n=17)
Number of subjects: 36
Study 17405803 — intervention group
Group type: COMPARATOR
Intervention: Falls prevention education group (n=19)
Number of subjects: 36
Study 15878564 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ATP
Number of subjects: 22
Study 15878564 — intervention group
Group type: COMPARATOR
Intervention: Delayed ATP
Number of subjects: 22
Study 11912358 — intervention group
Group type: EXPERIMENTAL
Intervention: Both-flaps group (trabeculectomy with intraoperative mitomycin C application under conjunctival and scleral flaps)
Number of subjects: 44
Study 11912358 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival group (subconjunctival application of mitomycin C)
Number of subjects: 44
Study 11912358 — intervention group
Group type: EXPERIMENTAL
Intervention: Both-flaps group
Number of subjects: 44
Study 11912358 — intervention group
Group type: COMPARATOR
Intervention: Subconjunctival group
Number of subjects: 44
Study 11547514 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg reboxetine
Number of subjects: 24
Study 11547514 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg reboxetine
Number of subjects: 24
Study 11547514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11547514 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (2 mg and 4 mg)
Number of subjects: 24
Study 9041914 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate 90 minutes before induction of anesthesia and epidural analgesia (group 1, n = 12)
Number of subjects: 24
Study 9041914 — intervention group
Group type: COMPARATOR
Intervention: Placebo 90 minutes before anesthesia and epidural analgesia (group 2, n = 12)
Number of subjects: 24
Study 8195265 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral support during operative procedures
Number of subjects: 80
Study 8195265 — intervention group
Group type: COMPARATOR
Intervention: Withheld enteral support during operative procedures
Number of subjects: 80
Study 3140587 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 5 mg daily for 4 cycles
Number of subjects: 22
Study 3140587 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 4 cycles
Number of subjects: 22
Study 29426008 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice-daily)
Number of subjects: 109
Study 29426008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 26830645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 89
Study 26830645 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 89
Study 25812927 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person brief intervention
Number of subjects: 360
Study 25812927 — intervention group
Group type: COMPARATOR
Intervention: Computerized brief intervention
Number of subjects: 360
Study 25812927 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline drug problem severity
Number of subjects: 360
Study 23796558 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine anticoagulation (n = 450)
Number of subjects: 673
Study 23796558 — intervention group
Group type: COMPARATOR
Intervention: Risk stratification and selective anticoagulation (n = 450)
Number of subjects: 673
Study 21062779 — intervention group
Group type: EXPERIMENTAL
Intervention: Staccato reperfusion (SR)
Number of subjects: 39
Study 18264130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole (7.4 nmol min(‐1) per 100 ml forearm)
Number of subjects: 40
Study 18264130 — intervention group
Group type: COMPARATOR
Intervention: Caffeine (90 microg min(‐1) per 100 ml volume)
Number of subjects: 40
Study 16800099 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nimesulide gel (Sulidin gel 1%)
Number of subjects: 97
Study 16800099 — intervention group
Group type: COMPARATOR
Intervention: Oral nimesulide (Mesulid tablet, 2 x 100 mg)
Number of subjects: 97
Study 14710104 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal vitamin with 400 IU of vitamin E and 500 mg of vitamin C
Number of subjects: 20
Study 14710104 — intervention group
Group type: COMPARATOR
Intervention: Control group (prenatal vitamin without additional vitamins)
Number of subjects: 20
Study 11008978 — intervention group
Group type: EXPERIMENTAL
Intervention: HELIOX (80% helium, 20% oxygen)
Number of subjects: 50
Study 11008978 — intervention group
Group type: COMPARATOR
Intervention: AIR (compressed room air)
Number of subjects: 50
Study 8997675 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical fixation method
Number of subjects: 20
Study 8997675 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical method
Number of subjects: 20
Study 8997675 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated method
Number of subjects: 20
Study 8997675 — intervention group
Group type: COMPARATOR
Intervention: Reference point-based method
Number of subjects: 20
Study 1361814 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-Flash system
Number of subjects: 46
Study 1361814 — intervention group
Group type: COMPARATOR
Intervention: Disconnect system
Number of subjects: 46
Study 31562517 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational activities at 2-3 years
Number of subjects: 4253
Study 31562517 — intervention group
Group type: EXPERIMENTAL
Intervention: Play at 2-3 years
Number of subjects: 4253
Study 31562517 — intervention group
Group type: EXPERIMENTAL
Intervention: Play at 4-5 years
Number of subjects: 4253
Study 31562517 — intervention group
Group type: COMPARATOR
Intervention: Screen time at all ages
Number of subjects: 4253
Study 29655277 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity interprofessional supportive care in cancer (LI‐IPSC‐C)
Number of subjects: 84
Study 29655277 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interprofessional supportive care in cancer (HI‐IPSC‐C)
Number of subjects: 84
Study 27318957 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisocial lying group (temptation resistance paradigm)
Number of subjects: 0
Study 27318957 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial lying group (undesirable gift scenario)
Number of subjects: 0
Study 27318957 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls in prosocial lying
Number of subjects: 0
Study 27318957 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys in prosocial lying
Number of subjects: 0
Study 27318957 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Expression Recognition Toolbox (CERT)
Number of subjects: 0
Study 24295556 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 μg once-daily (OD)
Number of subjects: 343
Study 24295556 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 μg twice-daily (BD)
Number of subjects: 343
Study 24295556 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 μg OD
Number of subjects: 343
Study 24295556 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 μg BD
Number of subjects: 343
Study 24295556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 22408263 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ICE
Number of subjects: 161
Study 22408263 — intervention group
Group type: EXPERIMENTAL
Intervention: R-DHAP
Number of subjects: 161
Study 22408263 — intervention group
Group type: COMPARATOR
Intervention: MYC(+) DLBCL patients
Number of subjects: 161
Study 22408263 — intervention group
Group type: COMPARATOR
Intervention: MYC(−) DLBCL patients
Number of subjects: 161
Study 21430407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 68
Study 21430407 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 68
Study 21430407 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 68
Study 18384246 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg/day
Number of subjects: 77
Study 18384246 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 mg/day
Number of subjects: 77
Study 18384246 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 150 mg/day
Number of subjects: 77
Study 18384246 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (all doses)
Number of subjects: 77
Study 18384246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 16863894 — intervention group
Group type: EXPERIMENTAL
Intervention: Home communication intervention (HCI) delivered by a telehealth device (Health Buddy) for 12 weeks
Number of subjects: 50
Study 16863894 — intervention group
Group type: EXPERIMENTAL
Intervention: Home communication intervention (HCI)
Number of subjects: 50
Study 16863894 — intervention group
Group type: COMPARATOR
Intervention: Control group (HHC only)
Number of subjects: 50
Study 12588464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (SUM) 6 mg s.c. injected in the morning and afternoon
Number of subjects: 16
Study 12588464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10960002 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous coating
Number of subjects: 0
Study 10960002 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyapatite coating
Number of subjects: 0
Study 10960002 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetabular augmentation screws or offset acetabular liners
Number of subjects: 0
Study 10960002 — intervention group
Group type: EXPERIMENTAL
Intervention: Offset acetabular liners
Number of subjects: 0
Study 10960002 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 0
Study 9303395 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg once daily)
Number of subjects: 590
Study 9303395 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone and/or cefuroxime axetil (1 to 2 g once to twice daily and 500 mg twice daily respectively)
Number of subjects: 590
Study 9303395 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 590
Study 9303395 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone and/or cefuroxime axetil
Number of subjects: 590
Study 8347269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (10 mg/kg p.o.) administered 12 hours post-operatively
Number of subjects: 53
Study 8347269 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin (10 mg/kg p.o.) administered 6 hours prior to transplant surgery
Number of subjects: 53
Study 3010693 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 9
Study 3010693 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (beta‐adrenoceptor antagonist)
Number of subjects: 9
Study 3010693 — intervention group
Group type: COMPARATOR
Intervention: Timolol (non-selective beta blocker)
Number of subjects: 9
Study 3010693 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (non-selective beta blocker)
Number of subjects: 9
Study 30219705 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxofylline 400 mg
Number of subjects: 483
Study 30219705 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 250 mg
Number of subjects: 483
Study 30219705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 27620393 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe Hypertension
Number of subjects: 987
Study 27620393 — intervention group
Group type: COMPARATOR
Intervention: Less Tight Control
Number of subjects: 987
Study 24480160 — intervention group
Group type: EXPERIMENTAL
Intervention: Curiam BT clinical decision support system
Number of subjects: 55
Study 24480160 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MR)
Number of subjects: 55
Study 22805388 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) therapy, administered three-times weekly for one year
Number of subjects: 15
Study 22805388 — intervention group
Group type: COMPARATOR
Intervention: No rhGH therapy (year before treatment)
Number of subjects: 15
Study 20038733 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection (ALND)
Number of subjects: 566
Study 20038733 — intervention group
Group type: COMPARATOR
Intervention: Axillary Radiation Therapy (ART)
Number of subjects: 566
Study 17991819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 35
Study 17991819 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 35
Study 17991819 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CBT and Wait-list)
Number of subjects: 35
Study 15943596 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted prenatally started intervention strategy including house dust mite impermeable bed coverings, education on breast feeding, hypoallergenic feeding, timing of introduction of solid food, and smoking cessation.
Number of subjects: 843
Study 15943596 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted prenatally started intervention strategy (high-risk group).
Number of subjects: 843
Study 15943596 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized randomized-clinical adherence trial (RCAT) for 92 high-risk infants.
Number of subjects: 843
Study 15943596 — intervention group
Group type: COMPARATOR
Intervention: Control group of low-risk infants (308 infants).
Number of subjects: 843
Study 12775858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic group (allergen avoidance measures from birth)
Number of subjects: 120
Study 12775858 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard advice)
Number of subjects: 120
Study 10351970 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (serum concentration, 1.29+/‐0.35 nmol/L)
Number of subjects: 43
Study 10351970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 10351970 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 43
Study 7573994 — intervention group
Group type: EXPERIMENTAL
Intervention: Perivenous technique (Group 2)
Number of subjects: 36
Study 7573994 — intervention group
Group type: COMPARATOR
Intervention: Selander technique (Group 1)
Number of subjects: 36
Study 7573994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 36
Study 2008268 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser treatment
Number of subjects: 151
Study 2008268 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon photocoagulation treatment
Number of subjects: 151
Study 2008268 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (not treated with argon or xenon)
Number of subjects: 151
Study 6750675 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (N = 108)
Number of subjects: 220
Study 6750675 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 112)
Number of subjects: 220
Study 30943337 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (30 mg, three monthly subcutaneous injections)
Number of subjects: 20
Study 30943337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30943337 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (during open-label phase)
Number of subjects: 20
Study 30943337 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 20
Study 28730694 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7697 (0.25-2.5 mg)
Number of subjects: 56
Study 28730694 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7697 (≥0.75 mg)
Number of subjects: 56
Study 28730694 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7697 (2.5 mg)
Number of subjects: 56
Study 28730694 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7697 (≥1.1 mg)
Number of subjects: 56
Study 28730694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 25773939 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire microcoil implantation method (performed for 51/99 nodules)
Number of subjects: 92
Study 25773939 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaving-microcoil-end implantation method (performed for 48/99 nodules)
Number of subjects: 92
Study 25773939 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided microcoil implantation
Number of subjects: 92
Study 22951345 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane dressing
Number of subjects: 38
Study 22951345 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 38
Study 21777555 — intervention group
Group type: EXPERIMENTAL
Intervention: Itopride (prokinetic agent) with a PPI
Number of subjects: 100
Study 21777555 — intervention group
Group type: COMPARATOR
Intervention: PPI and placebo
Number of subjects: 100
Study 19262420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Number of subjects: 50
Study 19262420 — intervention group
Group type: COMPARATOR
Intervention: Traditional approaches
Number of subjects: 50
Study 16876132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion and counseling
Number of subjects: 0
Study 16876132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16876132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 0
Study 14581124 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral delta-9-THC 5 mg
Number of subjects: 40
Study 14581124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10933104 — intervention group
Group type: EXPERIMENTAL
Intervention: AM‐MDPI at flow rate 54 L x min(‐1)
Number of subjects: 13
Study 10933104 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler at flow rate 58 L x min(‐1)
Number of subjects: 13
Study 10933104 — intervention group
Group type: EXPERIMENTAL
Intervention: AM‐MDPI at high flow rate 99 L x min(‐1)
Number of subjects: 13
Study 10933104 — intervention group
Group type: EXPERIMENTAL
Intervention: AM‐MDPI at flow rate 65 L x min(‐1)
Number of subjects: 13
Study 8932993 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 12
Study 8932993 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 12
Study 1567148 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine instillation
Number of subjects: 50
Study 1567148 — intervention group
Group type: COMPARATOR
Intervention: Inguinal field block
Number of subjects: 50
Study 3929301 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (AMP; 10 mg)
Number of subjects: 17
Study 3929301 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (AMP; 2.5 mg)
Number of subjects: 17
Study 3929301 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam (10 mg)
Number of subjects: 17
Study 3929301 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17
Study 29745441 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OACs) prescribed at hospital discharge
Number of subjects: 328
Study 29745441 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with patient frailty
Number of subjects: 328
Study 26354036 — intervention group
Group type: EXPERIMENTAL
Intervention: Frog storybooks (various stories)
Number of subjects: 831
Study 24666210 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry testing before and after bronchodilator (BD) using the EasyOne spirometer.
Number of subjects: 5176
Study 24666210 — intervention group
Group type: COMPARATOR
Intervention: Post-BD test sessions
Number of subjects: 5176
Study 22686204 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg daily for 1 year)
Number of subjects: 39
Study 22686204 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metformin)
Number of subjects: 39
Study 20115975 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Sinus Surgery Simulator (ES3) training
Number of subjects: 25
Study 20115975 — intervention group
Group type: COMPARATOR
Intervention: Control novice residents
Number of subjects: 25
Study 18062520 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.03 mg/kg followed by pethidine 20 mg intravenously
Number of subjects: 40
Study 18062520 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.03 mg/kg followed by tramadol 20 mg intravenously
Number of subjects: 40
Study 15691267 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac/MMF/S
Number of subjects: 489
Study 15691267 — intervention group
Group type: COMPARATOR
Intervention: Tac/Aza/S
Number of subjects: 489
Study 15691267 — intervention group
Group type: EXPERIMENTAL
Intervention: Tac/MMF
Number of subjects: 489
Study 15691267 — intervention group
Group type: COMPARATOR
Intervention: Tac/Aza
Number of subjects: 489
Study 12666828 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg Se-methionine daily, increased fish intake (at least three fish dinners weekly)
Number of subjects: 32
Study 12666828 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg selenite daily, increased fish intake (at least three fish dinners weekly)
Number of subjects: 32
Study 12666828 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets, increased fish intake (at least three fish dinners weekly)
Number of subjects: 32
Study 12666828 — intervention group
Group type: COMPARATOR
Intervention: No selenium supplementation, increased fish intake (at least three fish dinners weekly)
Number of subjects: 32
Study 10480522 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg t.i.d.)
Number of subjects: 9